NLS Pharmaceutics Ltd. announced that the European Patent Office (EPO) issued a Notice of Intention to Grant NLS's patent application covering a novel formulation of mazindol for treatment of ADHD and sleep related disorders. On November 23, 2020, the Canadian Intellectual Property Office (CIPO) issued a similar notice of allowance for the counterpart Canadian application. NLS awaits the impending grant of the European and Canadian patents. European Application No. 17724102, entitled "A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)", has been examined and allowed for issuance as a patent by the EPO on January 21, 2021. The allowed claims cover an invention related to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD), ADHD or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.